Nemolizumab-Ilto
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Comparison chart: Interleukin (IL) antagonists and oral JAK inhibitors for moderate to severe atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Novel therapeutic use of nemolizumab for refractory chronic scalp dysesthesia.
Journal: JAAD case reports
Published: February 02, 2026
The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis.
Journal: The British journal of dermatology
Published: June 25, 2025
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
Journal: Skin therapy letter
Published: May 22, 2025
Nemolizumab (Nemluvio) for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Comparison chart: Interleukin (IL) receptor antagonists for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Nemolizumab (Nemluvio®) for prurigo nodularis.
Journal: Trends in pharmacological sciences
Published: February 11, 2025
Showing 1-8 of 8
Last Updated: 04/28/2026